ArjoHuntleigh reports positive data from SARDS trial

ArjoHuntleigh has highlighted data from a new clinical study that showcases the benefits of prone positioning in the treatment of severe acute respiratory distress syndrome (SARDS).

Data from the study that appeared in the New England Journal of Medicines revealed that this technique significantly decreased mortality by 50 percent after 28 days and 42 percent after 90 days.

A significant reduction in ventilator-free days was also observed over similar periods for patients in the prone group, when compared to those left in a supine position.

ArjoHuntleigh offers a number of products that support prone therapy, such as the RotoProne Therapy System, TriaDyne Proventa Therapy System and Nimbus Professional System.

Dr Angel Delgado, director of clinical development and clinical sciences at ArjoHuntleigh, said: "It is very encouraging to see in this study that early application of prone positioning on SARDS patients has significant mortality benefits."

ArjoHuntleigh was formed in 2007 through the merger of Arjo and Huntleigh Technology and is a member of the Getinge Group.